<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00000643</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG 154</org_study_id>
    <secondary_id>11129</secondary_id>
    <nct_id>NCT00000643</nct_id>
  </id_info>
  <brief_title>Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients</brief_title>
  <official_title>Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      To evaluate the effectiveness of pyrimethamine (given with leucovorin calcium versus placebo
      (an inactive substance) for the primary prophylaxis (prevention) of cerebral toxoplasmosis in
      HIV-infected patients.

      Cerebral toxoplasmosis is one of the most frequently encountered opportunistic infections in
      the course of AIDS. The mortality (death) rate is estimated to be greater than 50 percent.
      Pyrimethamine is a drug that appears promising for the primary prevention of cerebral
      toxoplasmosis in HIV-infected patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cerebral toxoplasmosis is one of the most frequently encountered opportunistic infections in
      the course of AIDS. The mortality (death) rate is estimated to be greater than 50 percent.
      Pyrimethamine is a drug that appears promising for the primary prevention of cerebral
      toxoplasmosis in HIV-infected patients.

      AMENDED: 04-04-91 On the first day of therapy, a loading dose is given. After the first day,
      patients take pyrimethamine or placebo 3 times a week. Patients also take leucovorin calcium
      orally three times weekly. Enrollment occurs over approximately 12 months. All patients are
      followed on study until a common study close-out date and final analysis of the study. It is
      anticipated that this common close-out will occur when the mean duration of time on study
      therapy will be 3 years (approximately in January, 1994).

      ORIGINAL design: On the first day of treatment, patients receive a loading dose of
      pyrimethamine or placebo, plus of leucovorin calcium. After the first day, patients take
      pyrimethamine or placebo three times a week. Patients also take folinic acid orally three
      times weekly. The mean duration of study participation is 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 1994</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>150</enrollment>
  <condition>Toxoplasmosis, Cerebral</condition>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrimethamine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin calcium</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Concurrent Medication:

        Allowed:

          -  Zidovudine (AZT), didanosine (ddI), dideoxycytidine (ddC), erythropoietin (Eprex),
             other agents granted Treatment IND or expanded access status.

          -  Investigational triazoles.

          -  Pentamidine for primary prophylaxis of Pneumocystis carinii pneumonia (PCP).

        Patients with the following are excluded:

          -  History of cerebral toxoplasmosis or toxoplasmosis infection in any other organ or
             tissue.

          -  Focal neural abnormalities (except peripheral neuropathy) or mass lesions on a
             previous computerized tomography (CT) scan or magnetic resonance image (MRI), unless
             subsequent workup rules out toxoplasmosis, in which case abnormalities must have been
             stable for at least 2 months.

          -  Known or suspected allergy or severe intolerance to study drugs.

        Patients must have:

          -  Positive toxoplasma serology.

          -  HIV infection.

          -  Willingness and ability to comply with the protocol and capability of giving written
             informed consent.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions or symptoms are excluded:

          -  Current diagnosis of cerebral toxoplasmosis or toxoplasmosis infection in any other
             organ or tissue.

          -  Known or suspected allergy or severe intolerance to study drugs.

        Concurrent Medication:

        Excluded:

          -  Anticoagulants. Other antifolates, sulfonamides, fansidar, macrolides, 5-fluorouracil,
             dapsone, or any other agent with known activity against Toxoplasma gondii.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BJ Luft</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>JL Vilde</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>Stanford CRS</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Med. Ctr. CRS</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Miami AIDS CRS</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Med. Ctr. ACTG CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Univ. School of Medicine, Infectious Disease Research Clinic</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane Med. Ctr. - Charity Hosp. of New Orleans, ACTU</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Adult AIDS CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bmc Actg Crs</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota, ACTU</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis ConnectCare, Infectious Diseases Clinic</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington U CRS</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NJ Med. School CRS</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY - Buffalo, Erie County Medical Ctr.</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Med. Ctr. (Mt. Sinai)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NY Univ. HIV/AIDS CRS</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cornell University A2201</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan-Kettering Cancer Ctr.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Rochester ACTG CRS</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unc Aids Crs</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Univ. Med. Ctr. Adult CRS</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ. of Cincinnati CRS</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case CRS</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitt CRS</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rousseau F, Pueyo S, Morlat P, Hafner R, Chène G, Leport C, Luft BJ, Miro J, Aubertin J, Salamon R, Vildé JL. Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group. Clin Infect Dis. 1997 Mar;24(3):396-402.</citation>
    <PMID>9114191</PMID>
  </reference>
  <reference>
    <citation>Leport C, Chene G, Farinotti R, Ecobichon J-L, Petavin G, Sagardoy G, Morlat P, Hafner R, Luft B, Salamon R, Vilde J-L. Determination of pyrimethamine serum levels in a primary prophylaxis trial for toxoplasmic encephalitis. Conf Retroviruses Opportunistic Infect. 1996 Jan 28-Feb 1;3rd:159</citation>
  </reference>
  <reference>
    <citation>Leport C, Chêne G, Morlat P, Luft BJ, Rousseau F, Pueyo S, Hafner R, Miro J, Aubertin J, Salamon R, Vildé JL. Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group. J Infect Dis. 1996 Jan;173(1):91-7.</citation>
    <PMID>8537688</PMID>
  </reference>
  <reference>
    <citation>Pueyo S, Salmi LR, Chêne G, Leport C, Morlat P, Dequae L, Grégoire V, Hafner R, Vildé JL, Luft BJ, Aubertin J, Salamon R. Survival after AIDS-defining events in patients with &lt; 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):459-64.</citation>
    <PMID>9170421</PMID>
  </reference>
  <reference>
    <citation>Derouin F, Leport C, Pueyo S, Morlat P, Letrillart B, Chêne G, Ecobichon JL, Luft B, Aubertin J, Hafner R, Vildé JL, Salamon R. Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. AIDS. 1996 Nov;10(13):1521-7.</citation>
    <PMID>8931787</PMID>
  </reference>
  <reference>
    <citation>Chene G, Morlat P, Hafner R, Aboulker JP, Luft B, Dormont J, Vilde JL, Salamon R. Intent-to-treat versus on treatment analysis: how to interpret the results of a clinical trial? Experience from ANRS 005/ACTG 154 study. Natl Conf Hum Retroviruses Relat Infect (1st). 1993 Dec 12-16:100</citation>
  </reference>
  <reference>
    <citation>Chêne G, Morlat P, Leport C, Hafner R, Dequae L, Charreau I, Aboulker JP, Luft B, Aubertin J, Vildé JL, Salamon R. Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group. Control Clin Trials. 1998 Jun;19(3):233-48.</citation>
    <PMID>9620807</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>March 29, 2012</last_update_submitted>
  <last_update_submitted_qc>March 29, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 30, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Toxoplasmosis</keyword>
  <keyword>Pyrimethamine</keyword>
  <keyword>Leucovorin</keyword>
  <keyword>Drug Evaluation</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Brain Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Toxoplasmosis</mesh_term>
    <mesh_term>Toxoplasmosis, Cerebral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

